Publication Name	World Journal of Gastroenterology
Manuscript ID	4404
Country	South Korea

Received	2013-06-29 09:22
Peer-Review Started	2013-07-01 15:03
To Make the First Decision	2013-09-02 16:03
Return for Revision	2013-09-03 21:36
Revised	2013-09-30 10:50
Second Decision	2013-10-21 17:34
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2013-10-22 07:30
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-01-06 10:27
Publish the Manuscript Online	2014-01-20 17:10

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Autobiography
Article Title	Epirubicin, Cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma
Manuscript Source	Invited Manuscript
All Author List	Ji Eun Lee, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Young Kyoung You and Myung Ah Lee
Funding Agency and Grant Number
Corresponding Author	Myung Ah Lee, MD, PhD, Department of Internal Medicine, Hepato-Biliary-Pancreatic Cancer Center, Cancer Research Institute, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 137-040, South Korea. angelamd@catholic.ac.kr
Key Words	Hepatocellular carcinoma; Sorafenib; Epirubicin; Cisplatin; 5-FU
Core Tip	For advanced and metastatic hepatocellular carcinoma (HCC), sorafenib has been used as the standard systemic treatment. However, after failure to treat with sorafenib, no effective therapy is available. In the present study, we suggested that cytotoxic combination chemotherapy might be the another option for the treatment of progressive HCC. The patients with the age over 60 and a stable primary liver mass were benefit from the chemotherapy, leading to survival prolongation. Most clinical trials are currently focused on target agent because HCC is considered to be chemo-resistant cancer. Based on our data, new clinical trials using chemotherapy should be tried beyond sorafenib.
Publish Date	2014-01-20 17:10
Citation	Lee JE, Bae SH, Choi JY, Yoon SK, You YK, Lee MA. Epirubicin, Cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma. World J Gastroenterol 2014; 20(1): 235-241
URL	http://www.wjgnet.com/1007-9327/full/v20/i1/235.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i1.235

Full Article (PDF)	WJG-20-235.pdf
Full Article (Word)	WJG-20-235.doc
Manuscript File	4404-Review.docx
Answering Reviewers	4404-Answering reviewers.pdf
Copyright License Agreement	4404-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	4404-Language certificate.pdf
Peer-review Report	4404-Peer review(s).pdf
Scientific Editor Work List	4404-Scientific editor work list.doc